Ileana L Piña1, Vera Bittner2, Robert M Clare3, Ann Swank4, Andrew Kao5, Robert Safford6, Anil Nigam7, Denise Barnard8, Mary N Walsh9, Stephen J Ellis3, Steven J Keteyian10. 1. Division of Cardiology, Montefiore-Einstein Medical Center, Bronx, New York. Electronic address: ilpina@montefiore.org. 2. Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama. 3. Duke Clinical Research Institute, Duke University, Durham, North Carolina. 4. University of Louisville, Louisville, Kentucky. 5. University of Missouri-Kansas City, Kansas City, Missouri. 6. Mayo Clinic, Division of Cardiovascular Diseases, Jacksonville, Florida. 7. Montreal Heart Institute/University of Montreal, Montreal, Quebec, Canada. 8. University of California Health System, San Diego, California. 9. St. Vincent Heart Center of Indiana, Indianapolis, Indiana. 10. Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan.
Abstract
OBJECTIVES: The authors hypothesized that the women enrolled in the HF-ACTION (Heart Failure-A Controlled Trial Investigating Outcomes of Exercise TraiNing) trial and randomly assigned to exercise training (ET) would improve functional capacity as measured by peak oxygen uptake (VO2) compared with those in the usual care group. Furthermore, they hypothesized that the improvement in peak VO2 would correlate with prognosis. They explored whether exercise had a differential effect on outcomes in women versus men. BACKGROUND: There is less evidence for the benefit of ET in women with heart failure (HF) compared with men because of the small numbers of women studied. METHODS: HF-ACTION was a randomized trial of ET versus usual care in 2,331 patients with class II-IV HF and a left ventricular ejection fraction of ≤35%. Sex differences in the effects of randomized treatment on clinical outcomes were assessed through the use of a series of Cox proportional hazards models, controlling for covariates known to affect prognosis in HF-ACTION. RESULTS: Women had lower baseline peak VO2 and 6-min walk distance than did men (median, 13.4 vs. 14.9 ml/min/kg and 353 vs. 378 m, respectively). An increase in peak VO2 at 3 months was present in women and men in the ET group (mean ± SD; median, 0.88 ± 2.2, 0.80 and 0.77 ± 2.7, 0.60, respectively, women vs. men; p = 0.42). Women randomly assigned to ET had a significant reduction in the primary endpoint, (hazard ratio: 0.74) compared with men (hazard ratio: 0.99) randomly assigned to ET, with a significant treatment-by-sex interaction (p = 0.027). CONCLUSIONS: Although there is no significant difference between men and women in the effect of ET on peak VO2 change at 3 months, ET in women with HF is associated with a larger reduction in rate of the combined endpoint of all-cause mortality and hospital stay than in men.
RCT Entities:
OBJECTIVES: The authors hypothesized that the women enrolled in the HF-ACTION (Heart Failure-A Controlled Trial Investigating Outcomes of Exercise TraiNing) trial and randomly assigned to exercise training (ET) would improve functional capacity as measured by peak oxygen uptake (VO2) compared with those in the usual care group. Furthermore, they hypothesized that the improvement in peak VO2 would correlate with prognosis. They explored whether exercise had a differential effect on outcomes in women versus men. BACKGROUND: There is less evidence for the benefit of ET in women with heart failure (HF) compared with men because of the small numbers of women studied. METHODS: HF-ACTION was a randomized trial of ET versus usual care in 2,331 patients with class II-IV HF and a left ventricular ejection fraction of ≤35%. Sex differences in the effects of randomized treatment on clinical outcomes were assessed through the use of a series of Cox proportional hazards models, controlling for covariates known to affect prognosis in HF-ACTION. RESULTS:Women had lower baseline peak VO2 and 6-min walk distance than did men (median, 13.4 vs. 14.9 ml/min/kg and 353 vs. 378 m, respectively). An increase in peak VO2 at 3 months was present in women and men in the ET group (mean ± SD; median, 0.88 ± 2.2, 0.80 and 0.77 ± 2.7, 0.60, respectively, women vs. men; p = 0.42). Women randomly assigned to ET had a significant reduction in the primary endpoint, (hazard ratio: 0.74) compared with men (hazard ratio: 0.99) randomly assigned to ET, with a significant treatment-by-sex interaction (p = 0.027). CONCLUSIONS: Although there is no significant difference between men and women in the effect of ET on peak VO2 change at 3 months, ET in women with HF is associated with a larger reduction in rate of the combined endpoint of all-cause mortality and hospital stay than in men.
Authors: Jerome L Fleg; Lawton S Cooper; Barry A Borlaug; Mark J Haykowsky; William E Kraus; Benjamin D Levine; Marc A Pfeffer; Ileana L Piña; David C Poole; Gordon R Reeves; David J Whellan; Dalane W Kitzman Journal: Circ Heart Fail Date: 2015-01 Impact factor: 8.790
Authors: Linda Long; Ify R Mordi; Charlene Bridges; Viral A Sagar; Edward J Davies; Andrew Js Coats; Hasnain Dalal; Karen Rees; Sally J Singh; Rod S Taylor Journal: Cochrane Database Syst Rev Date: 2019-01-29
Authors: Jack O Garnham; Lee D Roberts; Talia Caspi; Moza M Al-Owais; Max Bullock; Peter P Swoboda; Aaron Koshy; John Gierula; Maria F Paton; Richard M Cubbon; Mark T Kearney; T Scott Bowen; Klaus K Witte Journal: J Cachexia Sarcopenia Muscle Date: 2019-08-20 Impact factor: 12.910
Authors: Katelyn E Uithoven; Joshua R Smith; Jose R Medina-Inojosa; Ray W Squires; Erik H Van Iterson; Thomas P Olson Journal: J Clin Med Date: 2019-01-19 Impact factor: 4.241